About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Market Cap
$0.13B
Employees
72
Listed Since
November 3, 2023
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.lexeotx.comPhone
(212) 547-9879
Headquarters
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
CIK
0001907108